UGT1A9 −275T>A/−2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus‐Treated Kidney Transplant Patients

@article{Schaik2009UGT1A9P,
  title={UGT1A9 −275T>A/−2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus‐Treated Kidney Transplant Patients},
  author={R H N Schaik and Madelon van Agteren and Johan W. de Fijter and Anders Hartmann and Jan Schmidt and Klemens Budde and D R J Kuypers and Yannick Le Meur and M. van der Werf and Richard D. Mamelok and Teun van Gelder},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2009},
  volume={86}
}
Mycophenolate mofetil (MMF) is an immunosuppressive drug commonly used in the context of kidney transplantation. Exposure to the active metabolite mycophenolic acid (MPA) is associated with risk of allograft rejection. MPA pharmacokinetics varies between individuals, the potential cause being the presence of genetic polymorphisms in key enzymes. We genotyped 338 kidney transplant patients for UGT1A8, UGT1A9, UGT2B7, and MRP2 polymorphisms and recorded MPA exposure and biopsy‐proven acute… 
Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial
TLDR
Genetic variability of CYP3A5 has an impact on TAC metabolism in pediatric renal transplant recipients, contributing partly to the variability of TAC exposure.
The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients
TLDR
P pretransplant genotyping for the CYP3A4*22 allele might help clinicians to identify patients at risk of DGF and poor renal function when treated with CsA, a substrate of cytochrome P450 3A4.
A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
TLDR
The CYP3A4 rs35599367C>T polymorphism is associated with a significantly altered Tac metabolism and therefore increases the risk of supratherapeutic Tac concentrations early after transplantation.
Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients
TLDR
Genotyping for ABCB1 or SLCO1B pretransplantation is unlikely to be of clinical value for individualization of MPA therapy.
Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
TLDR
The risk of subclinical acute rejection for recipients who cannot adapt in therapeutic drug monitoring (TDM) of MPA seems to be influenced by IMPDH1 rs2278293 polymorphism, which might help to improve MMF therapy.
Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients’ and donors’ ABCC2 gene variants, and their interactions
TLDR
Donors’ ABCC2 1249G>A polymorphism enhances the renal CsA effect, while recipients’ polymorphism seems to enhance the liver and the gutCsA effects.
SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients.
TLDR
Results suggest for the first time that carriers of the SLCO1B1*5 allele seem to be protected from MPA-related ADRs.
Impact of SLCO1B3 Polymorphisms on Clinical Outcomes in Lung Allograft Recipients Receiving Mycophenolic Acid
TLDR
It is concluded that hypofunctional SNPs in the SLCO1B3 gene are associated with an increased risk for acute rejection and allograft failure in lung transplant recipients treated with MPA.
Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis
TLDR
The results show that UGT1A9 polymorphisms can be used to identify patients with non-responsiveness to MPA, and patients with UGT2A8 and UGT3A8 polymorphisms might benefit from higher MPA dosage.
Association of UGT2B7, UGT1A9, ABCG2, and IL23R polymorphisms with rejection risk in kidney transplant patients
TLDR
SNPs of UGT2B7, UGT1A9, ABCG2, and IL23R genes may be useful as candidate markers for screening of risk graft rejection in renal transplant patients and may improve medical decisions, avoiding adverse effects.
...
...

References

SHOWING 1-10 OF 48 REFERENCES
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients
TLDR
It is concluded that patients expressing CYP3A5 need more tacrolimus to reach target concentrations and have a lower tac rolimus exposure shortly after transplantation, but this delay in reaching target concentrations did not result in an increased incidence of early BPAR and therefore, genotyping for CYP 3A5 is unlikely to improve short-term transplantation outcome.
C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
TLDR
The study demonstrated a significant impact of C-440T/T-331C SNPs in the promoter region of the UGT1A9 gene on MPA pharmacokinetics in renal allograft recipients and confirmed large interpatient variability of MPA exposure.
Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients
TLDR
In vitro and in vivo, AcMPAG production was increased in corticosteroid-induced rat liver microsomes, consistent with the observed in-vivo decrease of mycophenolic acid metabolites AUC0–9 h/dose with time after transplant.
Influence of Drug Transporters and UGT Polymorphisms on Pharmacokinetics of Phenolic glucuronide Metabolite of Mycophenolic Acid in Japanese Renal Transplant Recipients
TLDR
It is shown that MPAG pharmacokinetics were significantly influenced by SLCO1B1 and SLCo1B3 polymorphisms and not by UGT polymorphisms, and BCRP rather than multidrug resistance protein 2 seems to be the transporter associated with biliary excretion of MPAg.
Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.
TLDR
Exposure to total MPA, as determined by MPA clearance, significantly increased with increasing renal function, albumin level, and hemoglobin as well as decreasing cyclosporine predose level, which provides an indication for therapeutic drug monitoring as MPA exposure may be altered.
Multidrug Resistance Protein 2 Genetic Polymorphisms Influence Mycophenolic Acid Exposure in Renal Allograft Recipients
TLDR
The MRP2 C-24T and C-3972T polymorphisms protect renal transplant recipients from a decrease in MPA exposure associated with mild liver dysfunction and are suggested to be associated with a lower oral clearance of MPA in steady-state conditions.
Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
TLDR
The development of monitoring strategies for this drug appears to be promising, with the ability of predose levels or AUC(0-12h) to discriminate between cases with no complications and those with acute rejection, adverse events, or gastrointestinal disorders observed during the early posttransplant course confirmed.
Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance‐Associated Protein 2
  • D. Hesselink, R. V. van Hest, T. van Gelder
  • Biology, Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2005
TLDR
It is concluded that the pharmacokinetics of MMF are comparable in Mrp2‐deficient rats receiving either CsA or Tac as co‐medication, and this finding suggests thatCsA‐mediated inhibition of the biliary excretion of MPAG by theMrp2 transporter is the mechanism responsible for the interaction between Cs a and MMF.
Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors
TLDR
The effect of UGT1A8 and U GT1A9 variants on MPA metabolism appears to be modified by concomitant calcineurin inhibitor therapy.
...
...